RxDoctor Payments Data

Godwin Dsouza, MD

Internal Medicine · Chicago, ILNPI 1619915295

Payments from drug & device makers

$13,150in general payments, 2019–2025

Across 681 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$758
  • Pfizer$647
  • AstraZeneca$643
  • GSK$622
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$13,119100%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)65$1,304
Novo Nordisk61$1,186
Lilly USA, LLC36$758
Pfizer39$647
AstraZeneca36$643
GSK33$622
Boehringer Ingelheim22$493
E.r. Squibb & Sons, L.L.C.25$491
Johnson & Johnson(2 entities)22$435
Sumitomo Pharma America, Inc.22$426
Novartis20$414
Amgen(2 entities)22$391
Bayer18$381
Amarin Pharma, Inc.19$350
Merck21$349
Xeris Pharmaceuticals, Inc.15$298
Astellas Pharma US Inc14$273
Ardelyx, Inc.9$268
Kowa Pharmaceuticals America, Inc.11$207
Sunovion Pharmaceuticals Inc.13$198
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$188
Gilead11$172
UCB, Inc.6$166
Exact Sciences7$158
Otsuka America Pharmaceutical, Inc.8$139
Scilex Pharmaceuticals Inc.7$138
Vivus LLC7$130
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$129
Avanir Pharmaceuticals, Inc.7$128
Alpha Cognition USA, Inc.2$107
Hikma Pharmaceuticals USA8$106
Nestle Healthcare Nutrition Inc.6$103
Corcept Therapeutics4$101
Corium, LLC4$84
Dexcom, Inc.2$82
Sanofi-aventis U.S. LLC5$82
Lundbeck LLC5$80
Ironwood Pharmaceuticals, Inc4$62
Azurity Pharmaceuticals, Inc.3$56
Mannkind Corporation2$54
Biogen3$53
Acadia Pharmaceuticals Inc2$49
Abbott2$45
Scpharmaceuticals Inc.2$43
Viatris Specialty LLC2$38
Takeda Pharmaceuticals U.S.A., Inc.4$37
Paratek Pharmaceuticals, Inc.2$36
Cipher Pharmaceuticals US LLC1$33
Ultragenyx Pharmaceutical Inc.2$32
Esperion Therapeutics, Inc.2$30
Alkermes, Inc.1$29
Phathom Pharmaceuticals, Inc.1$28
Verona Pharma, Inc.1$27
Ascensia Diabetes Care US Inc.1$26
Medtronic2$25
Sun Pharmaceutical Industries Inc.1$24
CMP Pharma, Inc.1$23
Actelion Pharmaceuticals US, Inc.1$23
Lexicon Pharmaceuticals, Inc.1$21
Daiichi Sankyo Inc.1$20

How this compares

$13,150 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$711,008
Medicare patients
1,072
Services billed
9,699

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban2,265$892,683
JardianceEmpagliflozin520$332,199
TradjentaLinagliptin312$161,333
LinzessLinaclotide278$158,326
XareltoRivaroxaban334$148,525
JanuviaSitagliptin Phosphate190$126,708
Breo ElliptaFluticasone/Vilanterol285$117,166
OzempicSemaglutide97$114,891
EntrestoSacubitril/Valsartan190$114,352
NuplazidPimavanserin Tartrate20$105,948
Trelegy ElliptaFluticasone/Umeclidin/Vilanter114$87,747
TrulicityDulaglutide60$77,030
CreonLipase/Protease/Amylase48$72,154
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog213$57,243
TriumeqAbacavir/Dolutegravir/Lamivudi14$57,114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$647$892,6832,265 claims
Boehringer IngelheimJardiance, Tradjenta$493$493,532832 claims
AbbVieLinzess, Creon$1,304$230,479326 claims
GSKBreo Ellipta, Trelegy Ellipta$622$204,913399 claims
Johnson & JohnsonXarelto$435$148,525334 claims
MerckJanuvia$349$126,708190 claims
Novo NordiskOzempic$1,186$114,89197 claims
NovartisEntresto$414$114,352190 claims
Acadia Pharmaceuticals IncNuplazid$49$105,94820 claims
AstraZenecaFarxiga, Brilinta$643$87,984171 claims
Lilly USA, LLCTrulicity$758$77,03060 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$188$56,54325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →